S Bissonnette, R Habib, F Sampalis, S Boukas, JS Sampalis; for the Ezetrol® Add-On Investigators. Efficacy and tolerability of ezetimibe 10 mg/day coad-ministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study. Can J Cardiol 2006;22(12):1035–1044.
Please note that an error was printed in the 10-year coronary artery disease risk row of Table 4, in which the ‘high’ and ‘low’ risk patient groups were reversed. The authors regret the error. The corrected part of the table is as follows:
TABLE 4.
Comparison of subjects below and above target low-density lipoprotein cholesterol (LDL-C) levels at six weeks
| Patient group
|
||||
|---|---|---|---|---|
| Below target LDL-C (n=674) | Above target LDL-C (n=163) | P | ||
| 10-year coronary artery disease risk, n (%) | ||||
| High | 623 (92.4) | 154 (94.5) | 0.825‡ | |
| Moderate | 34 (5.0) | 6 (3.7) | ||
| Low | 17 (2.5) | 3 (1.8) | ||
P value based on χ2 test